BIZ BRIEF: Fujifilm to enter biosimilars drug joint venture

November 16, 2011

Fujifilm Corp. and Kyowa Hakko Kirin Co. will establish a joint venture in the spring of 2012 to develop highly reliable, high-quality and competitive products in the fast-growing biosimilars market, it was announced Nov. 16.

Biopharmaceuticals have become a growing presence in the pharmaceuticals market due to their unique efficacy and limited side effects, achieved through the use of proteins and other bio-molecules, which have a complex structure and deliver pharmacological effects that could not be attained in chemical synthesis.

Biosimilars are drugs that have equivalent or similar effects to those of biopharmaceuticals but are marketed by a different manufacturer after the original drug's patent expires.

The biosimilars market is set to expand rapidly throughout the world against the backdrop of escalating medical costs and patent expiration of a series of innovative biopharmaceuticals.

  • 1
submit to reddit